Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Allogeneic natural killer cell therapy
Melissa M. Berrien-Elliott, Miriam T. Jacobs, Todd A. Fehniger
Blood (2022) Vol. 141, Iss. 8, pp. 856-868
Open Access | Times Cited: 114

Showing 1-25 of 114 citing articles:

Natural killer cell therapies
Éric Vivier, Lucas Rebuffet, Émilie Narni-Mancinelli, et al.
Nature (2024) Vol. 626, Iss. 8000, pp. 727-736
Closed Access | Times Cited: 140
γδ T cells: origin and fate, subsets, diseases and immunotherapy
Yi Hu, Qinglin Hu, Yongsheng Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 111
Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions
Peilin Lu, Dongxue Ruan, Meiqi Huang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 83
Forks in the road for CAR T and CAR NK cell cancer therapies
Oula K. Dagher, Avery D. Posey
Nature Immunology (2023) Vol. 24, Iss. 12, pp. 1994-2007
Closed Access | Times Cited: 56
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Lei Peng, Giacomo Sferruzza, Luojia Yang, et al.
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 10, pp. 1089-1108
Open Access | Times Cited: 31
Advancing Natural Killer Cell Therapy: Genetic Engineering Strategies for Enhanced Cancer Immunotherapy
Joo Dong Park, Ha Eun Shin, Y. An, et al.
Annals of Laboratory Medicine (2025)
Open Access | Times Cited: 2
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Yalan Zhang, Weilin Zhou, Jianping Yang, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 29
T-BET and EOMES sustain mature human NK cell identity and antitumor function
Pamela Wong, Jennifer A. Foltz, Lily Chang, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 13
Open Access | Times Cited: 27
Natural Killer Cell-Based Immunotherapy against Glioblastoma
Takayuki Morimoto, Tsutomu Nakazawa, Ryosuke Maeoka, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2111-2111
Open Access | Times Cited: 24
CAR-T cell therapy for hematological malignancies: History, status and promise
Chao Wang, Jianpeng Wang, Shusheng Che, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e21776-e21776
Open Access | Times Cited: 24
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes
Nicholas A. Zorko, Allison Makovec, Andrew Elliott, et al.
Prostate Cancer and Prostatic Diseases (2024)
Open Access | Times Cited: 10
Cytokines drive the formation of memory-like NK cell subsets via epigenetic rewiring and transcriptional regulation
Jennifer A. Foltz, Jennifer Tran, Pamela Wong, et al.
Science Immunology (2024) Vol. 9, Iss. 96
Closed Access | Times Cited: 9
CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison
Lukas Egli, Meike Kaulfuß, Juliane Mietz, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Enhancing NK Cell Antitumor Activity With Natural Compounds: Research Advances and Molecular Mechanisms
Yu Wu, Mingxiao Yin, Wenjiao Xia, et al.
Phytotherapy Research (2025)
Closed Access | Times Cited: 1
Cell-based Immunotherapy in Esophageal Cancer
Masoud Lahouty, Amirhossein Soleymanzadeh, Sohrab Kazemi, et al.
Journal of drug targeting (2025), pp. 1-19
Closed Access | Times Cited: 1
CAR-T State of the Art and Future Challenges, A Regulatory Perspective
Lorenzo Giorgioni, Alessandra Ambrosone, Maria Francesca Cometa, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11803-11803
Open Access | Times Cited: 19
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Caroline Diorio, David T. Teachey, Stephan A. Grupp
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 8
Different origin-derived exosomes and their clinical advantages in cancer therapy
Xiaoyan Jin, Jing Zhang, Yufu Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Natural killer cell‐related anti‐tumour adoptive cell immunotherapy
Yuwen Qi, Ying Li, Hua Wang, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 11
Open Access | Times Cited: 5
Advances in CAR-NK cell therapy for hematological malignancies
Rui Yang, Yun Yang, Rui Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Frenemies in the Microenvironment: Harnessing Mast Cells for Cancer Immunotherapy
Roberta Sulsenti, Elena Jachetti
Pharmaceutics (2023) Vol. 15, Iss. 6, pp. 1692-1692
Open Access | Times Cited: 12
Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc
Julie O’Neal, Matthew Cooper, Julie Ritchey, et al.
Blood Advances (2023) Vol. 7, Iss. 20, pp. 6009-6022
Open Access | Times Cited: 11
Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy
Massimo Claudio Fantini, Philip M. Arlen, Kwong Y. Tsang
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Highlight of 2023: Unlocking the therapeutic potential of natural killer cells—advances in adaptive functions, cellular engineering and immunotherapy
Pui Yeng Lam, Fernando Souza‐Fonseca‐Guimaraes
Immunology and Cell Biology (2024) Vol. 102, Iss. 6, pp. 444-447
Closed Access | Times Cited: 4
Transcription factor KLF2 is associated with the dysfunctional status of NK cells and the prognosis of pediatric B-ALL patients
Fang Wu, Huimin Xu, Zhang Ben-shan
Frontiers in Oncology (2025) Vol. 14
Open Access
Page 1 - Next Page

Scroll to top